Understanding genetic changes in neuroblastoma cells to pave the way for targeted treatments
Investigation of the effects of DNA repair inhibitors in pre-clinical models of neuroblastomas with ATM, MYCN and TP53 abnormalities
Investigating a new approach to treating childhood brain tumours
Investigating the arginine auxotrophy of paediatric brain tumours
Understanding what goes wrong in cells that leads to malignant rhabdoid tumours
Unravelling the impact of SMARCB1 loss on the chromatin landscape in malignant rhabdoid tumor to identify novel therapeutic opportunities
Helping to develop research into antibody treatment
Investigation of ganglioside-specific receptor expression by tumour-infiltrating immune cells
Repurposing mebendazole and albendazole for acute myeloid leukaemia
Testing the use of mebendazole and albendazole for children with acute myeloid leukaemia, and investigating how the drugs work.
Developing a blood test to help identify high risk Wilms tumours
Circulating molecular biomarkers for earlier identification of high risk Wilms tumour
Investigating a new way of delivery drugs to the site of childhood brain tumours
Brain distribution models to select polymer-delivered drugs for the treatment of childhood brain cancers
Improving treatment and reducing side effects for children with B-cell NHL
Identification of new drug targets to improve treatment options and reduce treatment-related toxicity for children diagnosed with aggressive B-cell non-Hodgkin lymphoma (B-NHL)
Can a carbohydrate restricted diet help treat childhood brain tumours?
In vitro evaluation of the potential of glucose restriction as an adjuvant therapy for paediatric brain tumours